Braidwell’s Oruka Therapeutics ORKA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26.5M Buy
+278,164
New +$18.5M 0.98% 40
2026
Q1
Sell
-84,795
Closed -$2.57M 101
2025
Q4
$2.57M Sell
84,795
-1,297,555
-94% -$36.2M 0.08% 71
2025
Q3
$26.6M Sell
1,382,350
-142,492
-9% -$2.11M 0.79% 37
2025
Q2
$17.1M Sell
1,524,842
-47,584
-3% -$496K 0.58% 43
2025
Q1
$16.1M Buy
1,572,426
+424,750
+37% +$5.3M 0.57% 46
2024
Q4
$27.1M Buy
1,147,676
+631,950
+123% +$15.4M 0.8% 43
2024
Q3
$12.6M Buy
+515,726
New +$17.9M 0.36% 60

Other funds holding ORKA

Braidwell's ORKA Position: Q2 2026 in Review

Braidwell opened a new position in Oruka Therapeutics (ORKA) in Q2 2026: 278,164 shares worth $26.5M. The stake represents 0.98% of the portfolio and ranks #40 among its holdings. This is a return to the name: Braidwell previously reported a position in ORKA as recently as Q4 2025.

Braidwell first reported a position in ORKA in Q3 2024 and has held it in 7 quarters since. The position peaked at $27.1M in Q4 2024. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Braidwell held 278,164 shares of Oruka Therapeutics worth $26.5M as of Q2 2026.
  • Oruka Therapeutics was a new Braidwell position in Q2 2026.
  • Oruka Therapeutics made up 0.98% of Braidwell's portfolio in Q2 2026, its #40 holding.
  • Braidwell first reported a position in Oruka Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Braidwell's Oruka Therapeutics position peaked at $27.1M in Q4 2024.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.